Efficacy and tolerability of EPs® 7630 in patients with chronic obstructive pulmonary disease (COPD)

Submission date	Recruitment status No longer recruiting	Prospectively registered		
26/03/2009		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
14/05/2009	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
02/10/2013	Respiratory			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Dina A. Pliskevich

Contact details

Faculty Therapy No. 2 National Medical University 4 A, Podvisotskogo str. Kiev Ukraine 01103

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

701006.01.001

Study information

Scientific Title

Phase III study to prove the efficacy and tolerability of EPs® 7630 in patients aged greater than or equal to 18 years old with chronic obstructive pulmonary disease (COPD)

Study objectives

To determine the effect of EPs® 7630 (a liquid herbal drug preparation from the roots of Pelargonium sidoides) on time to occurrence of the first acute exacerbation in patients with chronic obstructive pulmonary disease (COPD) compared to placebo.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee and the State Pharmacological Centre of Ukraine approved on the 26/10/2005 (ref: 5.12-408/KE)

Study design

Phase III multicentre double-blind randomised placebo-controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Chronic obstructive pulmonary disease (COPD)

Interventions

EPs® 7630 solution or placebo 30 drops three times a day orally for 24 weeks as an add-on therapy to a standardised baseline treatment for COPD.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

EPs® 7630 (Pelargonium sidoides extract)

Primary outcome measure

Time to occurrence of first acute exacerbation during the treatment period of 24 weeks.

Secondary outcome measures

- 1. Number of acute exacerbations during the treatment period of 24 weeks
- 2. Duration of an acute exacerbation until it has subsided
- 3. Measurement of FEV1, forced vital capacity (FVC), and FEV1/FVC ratio every 4 weeks for 24 weeks
- 4. Measurement of FEV1, FVC, and FEV1/FVC ratio at begin and end of an acute exacerbation
- 5. Health status of the patients using the health-related Quality of Life questionnaire (EQ-5D) and St. George's Respiratory Questionnaire (SGRQ), assessed at baseline and every 4 weeks for 24 weeks
- 6. Treatment outcome using the Integrative Medicine Outcomes Scale (IMOS), assessed every 4 weeks for 24 weeks
- 7. Patient's satisfaction with treatment using the Integrative Medicine Patient Satisfaction Scale (IMPSS), assessed every 4 weeks for 24 weeks
- 8. Duration of limitation of physical activity during an acute exacerbation
- 9. Duration of patient's inability to work during an acute exacerbation
- 10. Consumption of paracetamol, Zedex, salmeterol, Berodual N, and budesonide by inhalation during the treatment period of 24 weeks
- 11. Consumption of salmeterol, budesonide, oral prednisone, Berodual N, and augmentinum (or ofloxacin) during an acute exacerbation
- 12. Pack year calculation and changes of smoking habits, assessed at baseline and every 4 weeks for 24 weeks
- 13. Adverse events surveillance: total duration of follow-up: 24 weeks
- 14. Laboratory values, assessed at baseline and every 4 weeks for 24 weeks

Overall study start date

13/03/2006

Completion date

16/06/2008

Eligibility

Key inclusion criteria

- 1. Aged greater than or equal to 18 years, both males and females
- 2. Written informed consent
- 3. History of chronic bronchitis (characterised by cough and sputum production on most days for a minimum of 3 months per year for at least 2 consecutive years)
- 4. Patients with stable COPD (no changes in volume or appearance of sputum or level of dyspnoea in the previous 4 weeks)
- 5. History of acute exacerbation greater than or equal to 3 times in the prior 12 months
- 6. Forced expiratory volume during one second (FEV1) less than 80% and greater than or equal to 30% predicted (COPD stage II, III)
- 7. Improvement of FEV1 during the initial FEV1 reversibility test is less than or equal to 0.3 l after two puffs of Berodual N

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

200

Key exclusion criteria

- 1. Patients suffering from cardiac diseases, pneumonia, active pulmonary tuberculosis, cystic fibrosis, bronchiectasis, lung cancer, acquired immune deficiency sydrome (AIDS)
- 2. Patients with asthma bronchiale
- 3. COPD patients in stage IV (FEV1 less than 30% predicted)
- 4. Patients with infiltrates or other abnormalities of the lungs indicating an active pathological process on chest x-ray
- 5. Patients with acute exacerbation within the last 4 weeks
- 6. Known concomitant bacterial infection or infections of respiratory tract
- 7. Concomitant medication with beta-blockers, angiotensin converting enzyme (ACE)-inhibitors, regular inhalative glucocorticoids (except in COPD patients stage III), oral glucocorticoids (except during an acute exacerbation), anticholinergics (except ipratropium bromide in Berodual N), beta-2-agonists other than salmeterol or fenoterol in Berodual N, analgetics other than paracetamol, mucolytics and antitussives other than Zedex, immunomodulators (e.g. bacterial vaccines), or coumarin-derivatives
- 8. Treatment with antibiotics, beta-blockers, ACE-inhibitors, anticholinergics (except ipratropium bromide in Berodual N), inhalative glucocorticoids (except in COPD patients stage III) or oral glucocorticoids within the last 4 weeks prior study inclusion
- 9. Known alcohol or drug abuse
- 10. Patients with tendency to bleed
- 11. Severe heart, renal or liver diseases and/or immunosuppression
- 12. Gastrointestinal disorders
- 13. Patients with known or supposed hypersensitivity against EPs® 7630
- 14. Females of child-bearing potential with no adequate contraception
- 15. Pregnancy or lactation
- 16. Patients participating in another clinical trial at the same time or have taken part in a clinical trial during the last 3 months before inclusion into this study
- 17. Irresponsible patients or those unable to understand nature, meaning and consequences of the trial

Date of first enrolment

13/03/2006

Date of final enrolment

16/06/2008

Locations

Countries of recruitment

Ukraine

Study participating centre Faculty Therapy No. 2

Kiev Ukraine 01103

Sponsor information

Organisation

Dr. Willmar Schwabe GmbH & Co. KG (Germany)

Sponsor details

c/o Dr. F. A. Malek Clinical Research Department Willmar-Schwabe-Str. 4 Karlsruhe Germany 76227

Sponsor type

Industry

Website

http://www.schwabepharma.com/international/

ROR

https://ror.org/043rrkc78

Funder(s)

Funder type

Industry

Funder Name

Dr Willmar Schwabe GmbH & Co. KG (Germany)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2013		Yes	No